2116 A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE). (September 2015) - Yamazaki, K.; Kuboki, Y.; Nishina, T.; Shinozaki, E.; Shitara, K.; Okamoto, W.; Kajiwara, T.; Matsumoto, T.; Tsushima, T.; Mochizuki, N.; Fukutani, M.; Nakamoto, M.; et al.